Related Experiment Video

Updated: May 15, 2026

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing
09:24

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing

Published on: June 9, 2016

Impact of genetic targets on primary brain tumor therapy: what's ready for prime time?

O Zalatimo1, C M Zoccoli, A Patel

  • 1Department of Neurosurgery, Penn State College of Medicine, Hershey Medical Center, EC 1001, 30 Hope Drive, Hershey, PA 17033, USA. ozz101@gmail.com

Advances in Experimental Medicine and Biology
|January 5, 2013
PubMed

Insights

Genetic markers are revolutionizing brain tumor treatment. Key markers like 1p/19q deletions, MGMT methylation, and IDH1 mutations are crucial for personalized therapies and improved patient outcomes in gliomas.

Area of Science:

  • Neuro-oncology
  • Molecular diagnostics
  • Genomics

Background:

  • Primary brain tumors represent a significant public health concern, with millions diagnosed annually.
  • Advances in molecular biology have shifted focus from treating tumor types to tailoring therapies based on individual tumor molecular profiles.
  • Specific genetic alterations are increasingly recognized as critical for prognosis and predicting treatment response.

Purpose of the Study:

  • To review established and emerging genetic markers with prognostic, predictive, and diagnostic value in primary brain tumors.
  • To highlight markers that are currently guiding clinical decisions and those under intensive investigation.
  • To explore novel approaches like serum profiling for discovering new biomarkers.

Main Methods:

  • Review of literature on genetic alterations in oligodendrogliomas, astrocytic tumors, and medulloblastomas.
  • Analysis of the prognostic and predictive significance of markers such as 1p/19q deletions, MGMT methylation, IDH1 mutations, and others.
  • Discussion of emerging markers and their potential clinical utility.

Main Results:

  • 1p/19q deletions are prognostic and predictive in oligodendrogliomas.
  • MGMT methylation and IDH1 mutations are potent prognostic markers for astrocytic tumors and gliomas.
  • Established markers like 1p/19q deletions, MGMT methylation, and IDH1 mutations define the 'triple negative' glioma subtype.
  • Markers for medulloblastomas (WNT activation, MYCC/MCYN amplification, TrkC expression) are prognostic but not yet treatment-driving.
  • Newer markers (CD133, 17q gain, TP53 mutations) require further validation.

Conclusions:

  • Genetic markers are transforming brain tumor management, enabling personalized medicine.
  • Validated markers like 1p/19q, MGMT, and IDH1 are essential for current clinical practice.
  • Ongoing research into novel biomarkers and serum profiling holds promise for future therapeutic strategies.

More Related Videos

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells05:02

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells

Published on: February 4, 2021

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device07:44

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device

Published on: May 2, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...